GLP-1 Agonist Therapy Center

Studies have shown that emotional eating and other eating behaviors could reduce weight loss when taking GLP-1 receptor agonists.

The case for why an SGLT2 inhibitor or GLP-1 receptor agonist should be initiated early in diabetes treatment, regardless of whether the patient is on insulin therapy.

Efpeglenatide has proven to significantly reduce several risk factors for cardiovascular and kidney disease. 

Liraglutide initiation after hospital discharge was comparable to insulin for glycemic control, with less incidence of hypoglycemia. 

Tirzepatide's dual-action may significantly impact a person's weight management and blood glucose compared to GLP-1 receptor agonists like semaglutide.

What if there is an adjunct option in managing type 1 diabetes beyond insulin analogs in the form of GLP-1 RAs?

Additional benefits are observed with dose escalation of semaglutide for patients with type 2 diabetes.

Dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1RAs create an additive effect for increased anti-inflammation and vascular protection.

GLP-1 receptor agonists are a pharmacologic treatment of type 2 diabetes with potential cardiorenal benefits.

Researchers compare the cardiovascular effectiveness and safety of GLP-1 agonists and SGLT-2 inhibitors in older adults.